Etamsylate

Etamsylate (also known as Dicynene) is a hemostatic agent, a type of medication that promotes hemostasis (the process that causes bleeding to stop). It is used to prevent or reduce bleeding in conditions like abnormal uterine bleeding, cleft palate, apoplexy, hemorrhagic disease of the newborn, epistaxis, and menorrhagia.

Mechanism of Action[edit | edit source]

Etamsylate works by promoting the adhesion of platelets to the collagen that is exposed when the blood vessels are damaged. It also stabilizes the blood vessel walls, reducing their fragility and permeability, and promotes vasoconstriction, which helps to reduce bleeding.

Side Effects[edit | edit source]

Like all medications, Etamsylate can cause side effects, although not everyone gets them. Some of the common side effects include nausea, headache, skin rash, and diarrhea. If these side effects persist or worsen, medical attention should be sought immediately.

Contraindications[edit | edit source]

Etamsylate should not be used in patients with known hypersensitivity to it or any of its ingredients. It is also contraindicated in patients with thromboembolic disorders due to the risk of clot formation.

Interactions[edit | edit source]

Etamsylate may interact with other medications, which can affect how it works or increase the risk of side effects. Some of the drugs that may interact with Etamsylate include anticoagulants like warfarin, heparin, and clopidogrel.

Dosage and Administration[edit | edit source]

The dosage of Etamsylate depends on the patient's condition and response to treatment. It is usually taken orally, but can also be given by injection in severe cases. The usual adult dose is 500 mg four times a day, starting one day before surgery and continuing for 2-4 days afterwards.

See Also[edit | edit source]

Etamsylate Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.